google-site-verification: googlec7193c3de77668c9.html

Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation

[
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).


Source link

Advertisements

See also  Periods may trigger pain for many who have sickle cell disease

Check Also

Protein LMOD1 offers new clues to muscle regeneration

[ Overexpression of LMOD1 influences the subcellular localization of SIRT1. Credit: eLife (2026). DOI: 10.7554/elife.104331 …

Study reveals multiple barriers to micronutrient-rich diets among vulnerable consumers

[ Credit: Vanessa Loring from Pexels Having access to enough food does not necessarily mean …

Heart failure deaths have doubled among younger, middle-aged Americans, report finds

[ Heart failure deaths are increasing steadily in the U.S., fueled by a rise in …

Leave a Reply

Available for Amazon Prime